Perioperative Management of Low Molecular Weight Heparins in Patients with Renal Insufficiency

Classification of Hemorrhagic Risk of Procedures

The American College of Chest Physicians recommends classifying surgical procedures according to their risk of bleeding, with high-risk procedures including neurosurgery, spinal surgery, cardiovascular surgery, and complex urologic surgery 1, 2
Procedures with low-moderate hemorrhagic risk include arthroscopy, laparoscopic cholecystectomy, abdominal hysterectomy, and colonoscopy with biopsy, with a bleeding risk of 0-2% at 30 days 1, 2
Procedures with minimal hemorrhagic risk include minor dermatologic procedures, cataract surgery, dental extractions, and pacemaker implantation, with a bleeding risk of approximately 0% at 30 days 1, 2

For high-risk hemorrhagic procedures, the American College of Chest Physicians recommends suspending enoxaparina/dalteparina 48 hours before surgery in patients with normal or mildly decreased renal function (ClCr ≥50 mL/min) 1, 3
For moderate renal insufficiency (ClCr 30-49 mL/min), suspension should be considered 48-72 hours before surgery due to the risk of bioaccumulation 1
For severe renal insufficiency (ClCr 15-29 mL/min), suspension should be considered at least 48-72 hours before surgery, with strong consideration of extending to 72 hours due to significant bioaccumulation and increased bleeding risk 1

The American College of Chest Physicians recommends initiating bridging therapy with therapeutic low molecular weight heparin 3 days before the procedure in high-risk thrombotic patients, with the last preoperative dose administered 24 hours before surgery at half the daily total dose 1, 3

For low-moderate risk hemorrhagic procedures, enoxaparina/dalteparina should be restarted 24 hours after the procedure at full dose, once adequate hemostasis is confirmed 1, 3
For high-risk hemorrhagic procedures, restart should be delayed 48-72 hours after surgery before restarting low molecular weight heparin at therapeutic dose 1, 3

The American College of Chest Physicians recommends obtaining a recent creatinine clearance before determining the duration of suspension, as this is crucial for precise dosing decisions 1
Enoxaparina bioaccumulates significantly when ClCr is <30 mL/min, increasing the risk of bleeding, while dalteparina shows less bioaccumulation even in severe renal insufficiency 1

In patients receiving therapeutic‑dose enoxaparin for pulmonary embolism, the medication should be withheld for 24 hours before both low‑bleeding‑risk and moderate/high‑bleeding‑risk procedures when renal function is normal (creatinine clearance ≥ 50 mL/min). This timing provides adequate drug clearance and minimizes peri‑procedural bleeding. American College of Cardiology/American Heart Association (ACC/AHA) 2024 guideline. 4
For high‑bleeding‑risk surgeries (e.g., neurosurgery, cardiovascular surgery, procedures requiring neuraxial anesthesia) in patients with normal renal function, the same 24‑hour pre‑procedure hold is recommended. ACC/AHA 2024 guideline. 4
In patients with moderate renal impairment (creatinine clearance 30–50 mL/min), the pre‑procedure hold should be extended to 48–72 hours for all types of procedures because of reduced drug elimination and risk of bioaccumulation. ACC/AHA 2024 guideline. 4
For patients with severe renal impairment (creatinine clearance < 30 mL/min), a minimum hold of 48 hours (preferably 72 hours) is advised for any procedure to ensure sufficient clearance of enoxaparin. (Derived from the same ACC/AHA recommendation). 4

After low‑ to moderate‑bleeding‑risk procedures, therapeutic enoxaparin may be restarted 24 hours post‑procedure once adequate hemostasis is confirmed. Blood journal guideline 2012. 5
Following high‑bleeding‑risk surgeries, the restart of therapeutic enoxaparin should be delayed 48–72 hours post‑procedure to balance the heightened bleeding risk against thrombotic risk. Blood journal guideline 2012. 5

For procedures with truly minimal bleeding risk (e.g., cataract surgery, minor dental extractions, minor dermatologic interventions), therapeutic enoxaparin can be continued without interruption. This approach is supported by the ACC/AHA 2024 guideline, which notes an essentially negligible risk of major bleeding within 30 days. 4

In patients with normal renal function, a standard 24‑hour hold of therapeutic enoxaparin provides sufficient clearance before procedural intervention, eliminating the need for additional bridging anticoagulation. ACC/AHA 2024 guideline. 4